Quest sells royalty rights to cancer drug ibrutinib for $485M

07/19/2013 | Genetic Engineering & Biotechnology News

Royalty Pharma agreed to pay $485 million in cash to acquire Quest Diagnostics' royalty rights from commercialization of ibrutinib, a drug candidate for chronic lymphocytic leukemia, small lymphocytic lymphoma and mantle cell lymphoma. The drug is being jointly developed by Pharmacyclics and Janssen Biotech. Quest obtained the royalty rights as part of its purchase of Celera in 2011.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL